PL2387580T3 - Pochodne deoksyaktagardyny - Google Patents

Pochodne deoksyaktagardyny

Info

Publication number
PL2387580T3
PL2387580T3 PL10700336T PL10700336T PL2387580T3 PL 2387580 T3 PL2387580 T3 PL 2387580T3 PL 10700336 T PL10700336 T PL 10700336T PL 10700336 T PL10700336 T PL 10700336T PL 2387580 T3 PL2387580 T3 PL 2387580T3
Authority
PL
Poland
Prior art keywords
deoxyactagardine
derivatives
deoxyactagardine derivatives
Prior art date
Application number
PL10700336T
Other languages
English (en)
Inventor
Sjoerd Nicolaas Wadman
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Publication of PL2387580T3 publication Critical patent/PL2387580T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10700336T 2009-01-14 2010-01-12 Pochodne deoksyaktagardyny PL2387580T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14449009P 2009-01-14 2009-01-14
PCT/GB2010/000042 WO2010082018A1 (en) 2009-01-14 2010-01-12 Deoxyactagardine derivatives
EP10700336.0A EP2387580B1 (en) 2009-01-14 2010-01-12 Deoxyactagardine derivatives

Publications (1)

Publication Number Publication Date
PL2387580T3 true PL2387580T3 (pl) 2015-01-30

Family

ID=42110329

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10700336T PL2387580T3 (pl) 2009-01-14 2010-01-12 Pochodne deoksyaktagardyny

Country Status (22)

Country Link
US (2) US8283371B2 (pl)
EP (1) EP2387580B1 (pl)
JP (1) JP5719312B2 (pl)
KR (1) KR20110119699A (pl)
CN (1) CN102348718B (pl)
AU (1) AU2010205472B2 (pl)
CA (1) CA2749278A1 (pl)
DK (1) DK2387580T3 (pl)
EA (1) EA021683B1 (pl)
ES (1) ES2520165T3 (pl)
HR (1) HRP20141084T1 (pl)
IL (1) IL213927A0 (pl)
MX (1) MX2011007313A (pl)
NZ (1) NZ594011A (pl)
PL (1) PL2387580T3 (pl)
PT (1) PT2387580E (pl)
RS (1) RS53586B1 (pl)
SG (1) SG172944A1 (pl)
SI (1) SI2387580T1 (pl)
TW (1) TWI453029B (pl)
WO (1) WO2010082018A1 (pl)
ZA (1) ZA201104991B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
AU2010205472B2 (en) 2009-01-14 2013-03-14 Novacta Biosystems Limited Deoxyactagardine derivatives
MX2011008043A (es) 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013508D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201213434D0 (en) 2012-07-27 2012-09-12 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) * 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (pl) * 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
ATE255165T1 (de) 1994-09-12 2003-12-15 Aventis Pharma Gmbh Rekombinantes mersacidin und verfahren zu seiner herstellung
CN1138560C (zh) 1995-06-23 2004-02-18 Ambi股份有限公司 控制对抗生素耐药的革兰氏阳性细菌的方法和治疗感染的方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) * 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
NZ522783A (en) 2000-06-28 2004-07-30 Smithkline Beecham P Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CA2501855A1 (en) 2002-10-10 2004-04-22 Molichem Medicines, Inc. Nucleic acids encoding duramycin
DE602004005203T2 (de) 2003-07-18 2007-11-22 Vicuron Pharmaceuticals, Inc. Antibiotikum 107891, dessen Faktoren A1 und A2, pharmazeutisch annehmbare Salzeund Zusammensetzungen und Verwendung davon
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
WO2007036706A1 (en) 2005-09-27 2007-04-05 Novacta Biosystems Limited Variants of the lantibiotic mersacidin and their use
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
ES2895666T3 (es) 2006-10-27 2022-02-22 Capsugel Belgium Nv Cápsulas duras de hidroxipropilmetilcelulosa y proceso de fabricación
WO2008151434A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
MX2011005425A (es) 2008-11-24 2011-09-27 Sentinella Pharmaceuticals Inc Sentinella Derivados de carboxiamida lantibiotica con actividad antibacteriana mejorada.
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
AU2010205472B2 (en) 2009-01-14 2013-03-14 Novacta Biosystems Limited Deoxyactagardine derivatives
MX2011008043A (es) 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.

Also Published As

Publication number Publication date
SG172944A1 (en) 2011-08-29
DK2387580T3 (da) 2014-10-13
JP5719312B2 (ja) 2015-05-13
EP2387580A1 (en) 2011-11-23
ZA201104991B (en) 2013-10-31
NZ594011A (en) 2013-12-20
CA2749278A1 (en) 2010-07-22
MX2011007313A (es) 2011-08-04
US20100179207A1 (en) 2010-07-15
AU2010205472A1 (en) 2011-07-28
KR20110119699A (ko) 2011-11-02
EA021683B1 (ru) 2015-08-31
EP2387580B1 (en) 2014-08-13
US8283371B2 (en) 2012-10-09
AU2010205472B2 (en) 2013-03-14
US8741945B2 (en) 2014-06-03
IL213927A0 (en) 2011-07-31
CN102348718B (zh) 2015-06-03
TW201029661A (en) 2010-08-16
EA201190071A1 (ru) 2012-06-29
CN102348718A (zh) 2012-02-08
WO2010082018A1 (en) 2010-07-22
HRP20141084T1 (hr) 2015-02-13
PT2387580E (pt) 2014-10-30
US20120277145A1 (en) 2012-11-01
RS53586B1 (en) 2015-02-27
JP2012515195A (ja) 2012-07-05
SI2387580T1 (sl) 2014-11-28
ES2520165T3 (es) 2014-11-11
TWI453029B (zh) 2014-09-21

Similar Documents

Publication Publication Date Title
HK1173142A1 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives n1--5-
HK1172893A1 (en) 5-fluoropyrimidinone derivatives 5-
ZA201203205B (en) Benzimidazole-imidazole derivatives
EP2420493A4 (en) HALOALKYLSULFONANILIDE DERIVATIVES
IL216007A0 (en) Isoxazole-pyridine derivatives
ZA201106855B (en) Oxasiazole derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
EP2433940A4 (en) SPIROIMIDAZOLONE DERIVATIVE
IL214941A0 (en) Isoxazole-pyrazole derivatives
ZA201104991B (en) Deoxyactagardine derivatives
HK1172894A1 (en) N1-acyl-5-fluoropyrimidinone derivatives n1--5-
HK1169623A1 (en) Pyrazinooxazepine derivatives
EP2401281A4 (en) PYRIMIDINPYRIMIDOINDAZOLDERIVAT
SI2492266T1 (sl) Derivat 5-hidroksipirimidin-4-karboksamida
EP2463290A4 (en) THIENOXAZEPINDERIVAT
EP2512482A4 (en) DERIVATIVES OF 2-ALDOXIMINO-5-FLUOROPYRIMIDINE
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
HK1173134A1 (en) Substituted halophenoxybenzamide derivatives
ZA201104279B (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives